Comparison · NCT03619213-5cadf859
Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation. Trial comparisons, record NCT03619213-5cadf859. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03619213-5cadf859
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.173 | 0.158 | 0.19 | wilson | |
| Risk in group 2 | 0.203 | 0.186 | 0.22 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0294 | -0.0525 | -0.00624 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.855 | 0.755 | 0.967 | log | |
| Odds ratio, group 1 over group 2 | 0.824 | 0.708 | 0.96 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dapa 10 mg than on Placebo | 34 | 19 | 160 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dapa 10 mg | Dapagliflozin 10 mg tablets administered once daily per oral use | 381 | 2,200 | OG000 |
| Group 2 | Placebo | Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use | 440 | 2,172 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation
- Description
Dual primary efficacy~Primary endpoint analysed in all patients randomised with LVEF \< 60% at baseline.~The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
- Time frame
- Up to 42.1 months
- Population
- Full analysis set
Source ClinicalTrials.gov
Trial
- Title
- Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
- NCT number
- NCT03619213
- Phases
- PHASE3
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Dapagliflozin, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2023-07-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03619213?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03619213-5cadf859